BofA raised the firm’s price target on Incyte (INCY) to $89 from $87 and keeps a Buy rating on the shares. After Incyte reported Q1 results, the firm cites mainly higher cash estimates for its revised price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte Reports Strong Q1 2025 Financial Growth
- Incyte’s Q1 2025 Earnings: Strong Growth and Optimism
- Incyte’s Promising Growth Potential and Strategic Positioning Amidst Market Challenges
- Morning Movers: Hims & Hers skyrockets following obesity pact with Novo Nordisk
- Incyte’s Mixed Performance and Future Uncertainties Justify Hold Rating